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Primary cutaneous lymphomas are cur-
rently classified by the European Organi-
zation for Research and Treatment of
Cancer (EORTC) classification or the
World Health Organization (WHO) classifi-
cation, but both systems have shortcom-
ings. In particular, differences in the clas-
sification of cutaneous T-cell lymphomas
other than mycosis fungoides, Se´zary
syndrome, and the group of primary cuta-
neous CD30 lymphoproliferative disor-
ders and the classification and terminol-
ogy of different types of cutaneous B-cell
lymphomas have resulted in consider-
able debate and confusion. During recent
consensus meetings representatives of
both systems reached agreement on a
new classification, which is now called
the WHO-EORTC classification. In this
paper we describe the characteristic fea-
tures of the different primary cutaneous
lymphomas and other hematologic neo-
plasms frequently presenting in the skin,
and discuss differences with the previous
classification schemes. In addition, the
relative frequency and survival data of
1905 patients with primary cutaneous lym-
phomas derived from Dutch and Austrian
registries for primary cutaneous lympho-
mas are presented to illustrate the clinical
significance of this new classification.
(Blood. 2005;105:3768-3785)
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Introduction
A variety of T- and B-cell neoplasms can involve the skin, either
primarily or secondarily. The term “primary cutaneous lymphoma”
refers to cutaneous T-cell lymphomas (CTCLs) and cutaneous
B-cell lymphomas (CBCLs) that present in the skin with no
evidence of extracutaneous disease at the time of diagnosis. After
the gastrointestinal tract, the skin is the second most common site
of extranodal non-Hodgkin lymphoma, with an estimated annual
incidence of 1:100,000.1
Primary cutaneous lymphomas often have a completely differ-
ent clinical behavior and prognosis from histologically similar
systemic lymphomas, which may involve the skin secondarily, and
therefore require different types of treatment. For that reason,
recent classification systems for non-Hodgkin lymphomas such as
the European Organization for Research and Treatment of Cancer
(EORTC) classification for primary cutaneous lymphomas and the
World Health Organization (WHO) classification for tumors of
hematopoietic and lymphoid tissues included primary cutaneous
lymphomas as separate entities.2,3 In the EORTC classification,
distinction was made between primary cutaneous lymphomas with
an indolent, intermediate, or aggressive clinical behavior. The
clinical validity of this classification has been validated by several
large studies, including follow-up data of more than 1300 patients
with a primary cutaneous lymphoma.2,4,5 Although there was
consensus between the EORTC and WHO classifications on the
classification of most types of CTCLs, remaining differences
between the 2 classification systems, in particular the controversy
on the definition and terminology of the different types of CBCLs,
has resulted in considerable debate and confusion.6-9
During consensus meetings in Lyon, France (September 2003)
and Zurich, Switzerland (January 2004), these differences were
resolved by representatives of both classification systems, and a
consensus classification was developed (Table 1). In this report we
present the new WHO-EORTC classification for cutaneous lympho-
mas. This review will focus on primary cutaneous lymphomas and
a few other conditions that frequently first present in the skin, such
as CD4/CD56 hematodermic neoplasm (formerly also known as
blastic natural killer [NK] cell lymphoma) and adult T-cell
leukemia/lymphoma. Other neoplasms that may also first present in
the skin in a minority of cases, such as precursor B-lymphoblastic
leukemia/lymphoma and acute myeloid leukemia, and secondary
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cutaneous manifestations of systemic lymphomas, are not dis-
cussed, but will be included in the monograph to be published in
the WHO Blue Book series in 2005. After a discussion of the 2
most controversial groups of cutaneous lymphomas that were
defined differently in the original EORTC and WHO classification
schemes, the main features of the different types of primary
cutaneous lymphoma are presented. In Table 2 the relative fre-
quency and survival of 1905 patients with primary cutaneous
lymphomas derived from Dutch and Austrian cutaneous lymphoma
registries are presented, to illustrate the clinical significance of the
WHO-EORTC classification.
Classification of CTCLs other than mycosis fungoides, Se´zary
syndrome, and primary cutaneous CD30 lymphoproliferations
The classification of this remaining group of CTCLs is difficult and
confusing, which is not surprising given the heterogeneity and
rarity of these tumors. Together, they constitute less than 10% of all
CTCLs.2,5 With few exceptions, these lymphomas are clinically
aggressive and in most cases systemic chemotherapy is required. In
the EORTC classification, most of these lymphomas were grouped
as primary cutaneous CD30 large T-cell lymphoma or in the
provisional group of primary cutaneous small/medium-sized
pleomorphic CTCLs. Distinction between these 2 categories,
which is based on the presence of more or less than 30% large
neoplastic T cells, was considered useful because several studies
demonstrated a significant difference in survival between these 2
groups.2,4,5,10 Recent studies suggest, however, that this favorable
prognosis is restricted to small/medium-sized pleomorphic CTCLs
with a CD4 T-cell phenotype, in particular those that present with
localized disease, in contrast to those with a CD8 T-cell pheno-
type.11 Moreover, the EORTC category of CD30 large-cell
CTCLs has become quite heterogeneous through the recognition of
new diagnostic categories, such as subcutaneous panniculitis-like
T-cell lymphoma (SPTL),12-17 extranodal NK/T-cell lymphoma,
nasal type,18-20 CD4/CD56 hematodermic neoplasm (blastic
NK-cell lymphoma),21-24 aggressive epidermotropic CD8
Table 1. WHO-EORTC classification of cutaneous lymphomas
with primary cutaneous manifestations
Cutaneous T-cell and NK-cell lymphomas
Mycosis fungoides
MF variants and subtypes
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Se´zary syndrome
Adult T-cell leukemia/lymphoma
Primary cutaneous CD30 lymphoproliferative disorders
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma*
Extranodal NK/T-cell lymphoma, nasal type
Primary cutaneous peripheral T-cell lymphoma, unspecified
Primary cutaneous aggressive epidermotropic CD8 T-cell lymphoma
(provisional)
Cutaneous / T-cell lymphoma (provisional)
Primary cutaneous CD4 small/medium-sized pleomorphic T-cell lymphoma
(provisional)
Cutaneous B-cell lymphomas
Primary cutaneous marginal zone B-cell lymphoma
Primary cutaneous follicle center lymphoma
Primary cutaneous diffuse large B-cell lymphoma, leg type
Primary cutaneous diffuse large B-cell lymphoma, other
Intravascular large B-cell lymphoma
Precursor hematologic neoplasm
CD4/CD56 hematodermic neoplasm (blastic NK-cell lymphoma)†
Table 2. Relative frequency and disease-specific 5-year survival of 1905 primary cutaneous lymphomas classified
according to the WHO-EORTC classification
WHO-EORTC classification No. Frequency, %*
Disease-specific
5-year survival, %
Cutaneous T-cell lymphoma
Indolent clinical behavior
Mycosis fungoides 800 44 88
Folliculotropic MF 86 4 80
Pagetoid reticulosis 14  1 100
Granulomatous slack skin 4  1 100
Primary cutaneous anaplastic large cell lymphoma 146 8 95
Lymphomatoid papulosis 236 12 100
Subcutaneous panniculitis-like T-cell lymphoma 18 1 82
Primary cutaneous CD4 small/medium pleomorphic T-cell lymphoma† 39 2 75
Aggressive clinical behavior
Se´zary syndrome 52 3 24
Primary cutaneous NK/T-cell lymphoma, nasal-type 7  1 NR
Primary cutaneous aggressive CD8 T-cell lymphoma† 14  1 18
Primary cutaneous / T-cell lymphoma† 13  1 NR
Primary cutaneous peripheral T-cell lymphoma, unspecified‡ 47 2 16
Cutaneous B-cell lymphoma
Indolent clinical behavior
Primary cutaneous marginal zone B-cell lymphoma 127 7 99
Primary cutaneous follicle center lymphoma 207 11 95
Intermediate clinical behavior
Primary cutaneous diffuse large B-cell lymphoma, leg type 85 4 55
Primary cutaneous diffuse large B-cell lymphoma, other 4  1 50
Primary cutaneous intravascular large B-cell lymphoma 6  1 65
NR indicates not reached.
*Data are based on 1905 patients with a primary cutaneous lymphoma registered at the Dutch and Austrian Cutaneous Lymphoma Group between 1986 and 2002.
†Primary cutaneous peripheral T-cell lymphoma, unspecified excluding the three provisional entities indicated with a double dagger (‡).
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CTCL,16,25,26 and cutaneous gamma/delta T-cell lymphoma.27-31 In
the WHO classification, SPTL, nasal-type NK/T-cell lymphoma,
and blastic NK-cell lymphoma were included as separate entities,
whereas the other entities were part of the broad category of
peripheral T-cell lymphoma (PTL), unspecified.
In the WHO-EORTC classification, extranodal NK/T-cell lym-
phoma, nasal type, and CD4/CD56 hematodermic neoplasm
(blastic NK-cell lymphoma), are defined as separate entities.
Recent studies showed both clinical, histologic, and immunopheno-
typical differences between cases of SPTL with an / T-cell
phenotype and those with a / T-cell phenotype, suggesting that
these may represent different entities. Whereas SPTLs with an /
T-cell phenotype are homogeneous with a rather indolent clinical
behavior in many patients, SPTLs with a / T-cell phenotype
overlap with other types of / T/NK-cell lymphoma and
invariably run a very aggressive clinical course.14,16,17,31,32
We therefore suggest that the term “SPTL” be restricted for
SPTLs with an / T-cell phenotype.32 Recent studies have
suggested that some disorders can be separated out as provisional
entities from the broad group of “PTL, unspecified,” in the WHO
classification. These include aggressive epidermotropic CD8
CTCL, cutaneous gamma-delta T-cell lymphoma (including cases
formerly diagnosed as SPTL with a gamma/delta phenotype), and
primary cutaneous small-medium CD4 T-cell lymphoma. In the
WHO-EORTC classification the term “PTL, unspecified,” is main-
tained for remaining cases that do not fit into either of these
provisional entities.
Primary cutaneous follicle-center cell lymphoma and primary
cutaneous diffuse large B-cell lymphoma
In recent years, the EORTC categories of primary cutaneous
follicle center cell lymphoma (PCFCCL) and primary cutaneous
large B-cell lymphoma of the leg (PCLBCL-leg) have been the
subject of much debate. The term PCFCCL was introduced in 1987
as a term encompassing cutaneous lymphomas that were composed
of cells with the morphology of follicle center cells (ie, centroblasts
and [large] centrocytes), and that were classified as either centro-
blastic/centrocytic or centroblastic lymphoma according to criteria
of the Kiel classification.33 Whereas small and early lesions may
show both small and large neoplastic B cells and many admixed
T cells, and may have a partly follicular growth pattern,
tumorous lesions generally show a predominance of large B
cells, particularly large cleaved or multilobated cells, and less
frequently a predominance of typical centroblasts and immuno-
blasts.33-35 In contrast to nodal follicular lymphomas, PCFCCLs
do generally not express bcl-2 and are not typically associated
with the t(14;18) translocation.36,37 Clinically, most patients
present with localized skin lesions on the head or trunk and,
regardless of the histologic subclassification on the basis of
growth pattern or number of blast cells, are highly responsive to
radiotherapy and have an excellent prognosis.2,4,5,33,34,35,38
The WHO classification approached these lesions from a
different perspective. PCFCCLs with a partly follicular growth
pattern were included as a variant of follicular lymphoma and
designated cutaneous follicle center lymphoma, while cases with a
diffuse growth pattern and a predominance of large centrocytes or
centroblasts were generally classified as diffuse large B-cell
lymphoma. The designation of this latter group as diffuse large
B-cell lymphoma was controversial, since it could lead to overtreat-
ment with muliagent chemotherapy rather than radiotherapy.
PCLBCL-leg was initially recognized as a subgroup of PCF-
CCL with a somewhat different histology and a more unfavorable
prognosis.39 In the EORTC classification it was included as a
separate subgroup. PCLBCL-leg particularly affects elderly people
and has a higher relapse rate and a more unfavorable prognosis than
PCFCCL with a diffuse large B-cell morphology.40 Histologically,
they have a predominance of centroblasts and immunoblasts rather
than large centrocytes, and consistently strongly express bcl-2
protein.41 Although delineation of this subgroup based on site has
been criticized,6,8 recent clinicopathologic and genetic studies
further support that PCFCCL and PCLBCL-leg are distinct groups
of CBCL.42-46
During the consensus meeting in Zurich, histologic slides of a
large number of PCFCCLs and PCLBCL-leg’s were reviewed,
together with the immunophenotype and clinical data. It was
recognized that PCFCCLs as defined in the EORTC classification
indeed form a spectrum of disease that includes cases with a
follicular, a follicular and diffuse, and a diffuse growth pattern, and
a range of cellular composition from predominantly small centro-
cytes to a predominance of large centrocytes with variable numbers
of admixed centroblasts and immunoblasts. This entity will further
be referred to as “primary cutaneous follicle center lymphoma”
(PCFCL). The group of PCLBCL-leg was also recognized as a
separate entity. According to the results of a recent multicenter
study, it is also clear that cases with a similar morphology
(predominance or cohesive sheets of centroblasts and immuno-
blasts), immunophenotype (strong expression of bcl-2 and Mum-1/
IRF4), and prognosis may arise at sites other than the leg.42 In the
WHO-EORTC classification the term “PCLBCL, leg type” is
proposed for both lesions on the legs and similar lesions at other
skin sites. In addition, the term “PCLBCL, other” is introduced for
rare cases of PCLBCL not belonging to the group of PCLBCL, leg
type, or PCFCL with a diffuse infiltration of large centrocytes.
Cutaneous T-cell lymphomas
Mycosis fungoides
Definition. Mycosis fungoides (MF) is a commonly epidermo-
tropic CTCL characterized by a proliferation of small- to medium-
sized T lymphocytes with cerebriform nuclei. The term MF should
be used only for the classical “Alibert-Bazin” type characterized by
the evolution of patches, plaques, and tumors, or for variants
showing a similar clinical course. MF is the most common type of
CTCL and accounts for almost 50% of all primary cutaneous
lymphomas (Table 2).
Clinical features. MF typically affects older adults (median
age at diagnosis: 55-60 years; male-to-female ratio: 1.6-2.0:1), but
may occur in children and adolescents.47-50 MF has an indolent
clinical course with slow progression over years or sometimes
decades, from patches to more infiltrated plaques and eventually to
tumors (Figure 1A). In some patients, lymph nodes and visceral
organs may become involved in the later stages of the disease. The
initial skin lesions have a predilection for the buttocks and other
sun-protected areas. Patients with tumor-stage MF characteristi-
cally show a combination of patches, plaques, and tumors, which
often show ulceration. If only tumors are present, without preced-
ing or concurrent patches or plaques, a diagnosis of MF is highly
unlikely and another type of CTCL should be considered.
Histopathology. Early patch lesions in MF show superficial
bandlike or lichenoid infiltrates, mainly consisting of lymphocytes
and histiocytes. Atypical cells with small- to medium-sized, highly
indented (cerebriform), and sometimes hyperchromatic nuclei are
few, and mostly confined to the epidermis (epidermotropism). They
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characteristically colonize the basal layer of the epidermis either as
single, often haloed cells, or in a linear configuration.51 In typical
plaques, epidermotropism is generally more pronounced than in the
patches (Figure 1B). The presence of intraepidermal collections of
atypical cells (Pautrier microabscesses) is a highly characteristic
feature, but is observed in only a minority of cases.52 With
progression to tumor stage, the dermal infiltrates become more
diffuse and epidermotropism may be lost. The tumor cells increase
in number and size, showing variable proportions of small,
medium-sized, to large cerebriform cells, blast cells with promi-
nent nuclei, and intermediate forms. Transformation to a diffuse
large-cell lymphoma that may be either CD30 or CD30 may
occur and is often associated with a poor prognosis.53
Immunophenotype. The neoplastic cells in MF have a mature
CD3, CD4, CD45RO, CD8 memory T-cell phenotype. In rare
cases of otherwise classical, MF a CD4, CD8 mature T-cell
phenotype may be seen.25,26,54,55 Such cases have the same clinical
behavior and prognosis as CD4 cases, and should not be
considered separately. Demonstration of an aberrant phenotype (eg,
loss of pan–T-cell antigens such as CD2, CD3, and CD5) is often
seen and is an important adjunct in the diagnosis of MF.54
Expression of cytotoxic proteins (T-cell intracellular antigen-1
[TIA-1], granzyme B) by the neoplastic CD4 T-cells has been
detected in 10% of MF plaques, but is much more common in
tumors showing blastic transformation.56
Genetic features. Clonal T-cell receptor gene rearrangements
are detected in most cases.51 Many structural and numerical
chromosomal abnormalities have been described, in particular in
the advanced stages of MF, but recurrent, MF-specific chromo-
somal translocations have not been identified.51,57 Chromosomal
loss at 10q and abnormalities in p15, p16, and p53 tumor
suppressor genes are commonly found in patients with MF.51
Prognosis and predictive factors. The prognosis of patients
with MF is dependent on stage, and in particular the type and extent
of skin lesions and the presence of extracutaneous disease.47-49
Patients with limited patch/plaque-stage MF have a similar life
expectancy to an age-, sex-, and race-matched control population.
In recent studies, 10-year disease-specific survivals were 97%-98%
for patients with limited patch/plaque disease (covering less than
10% of the skin surface), 83% for patients with generalized
patch/plaque disease (covering more than 10% of the skin surface),
42% for patients with tumor stage disease, and about 20% for
patients with histologically documented lymph node involve-
ment.47-49 Patients with effaced lymph nodes, visceral involvement,
and transformation into a large T-cell lymphoma have an aggres-
sive clinical course. Patients usually die of systemic involvement or
infections.
Therapy. As long as the disease is confined to the skin,
skin-targeted therapies as photo (chemo)–therapy (eg, psoralen
plus ultraviolet A [PUVA]), topical application of nitrogen mustard
or chlormustine (BCNU), or radiotherapy, including total skin
electron beam irradiation, are preferred.58-60 In patients with limited
patch-stage disease topical steroids or bexarotene gel can be used.
Biologicals such as interferon alpha and other cytokines (eg,
interleukin-12 [IL-12]), traditional and new retinoids such as
bexarotene, and receptor-targeted cytotoxic fusion proteins (eg,
DAB389IL-2; denileukin diftitox), are increasingly used in the
treatment of MF.58,60-63 However, the exact place of these new
treatments, either as single-agent therapy or in combination with
other therapies (eg, PUVA) in the treatment of MF remains to be
established. Multiagent chemotherapy is generally used in case of
unequivocal lymph node or systemic involvement, or in cases with
widespread tumor-stage MF refractory to skin-targeted therapies,
but should not be considered in early patch/plaque stage disease.64
Variants and subtypes of mycosis fungoides
Apart from the classical Alibert-Bazin type of MF, many clinical
and/or histologic variants have been reported. Clinical variants,
such as bullous and hyper- or hypopigmented MF, have a clinical
behavior similar to that of classical MF, and therefore are not
considered separately. In contrast, folliculotropic MF (MF-
associated follicular mucinosis), pagetoid reticulosis, and granulo-
matous slack skin have distinctive clinicopathologic features, and
are therefore considered separately.
Folliculotropic MF. Definition. Folliculotropic MF is a vari-
ant of MF characterized by the presence of folliculotropic infil-
trates, often with sparing of the epidermis, and preferential
involvement of the head and neck area. Most cases show mucinous
degeneration of the hair follicles (follicular mucinosis) and are
traditionally designated as MF-associated follicular mucinosis.
Similar cases, but without follicular mucinosis, have been reported
as folliculocentric or pilotropic MF.65 Recent studies showed no
differences in clinical presentation and clinical behavior between
cases of folliculotropic MF with or without associated follicular
mucinosis, and suggested that cases with a preferential infiltration
of hair follicles with or without the presence of mucin should be
termed “follicular MF” or “folliculotropic MF.”66-68 In the WHO-
EORTC classification, folliculotropic MF is preferred as the most
appropriate term. From a biologic point of view, the most relevant
feature in both cases with and without associated follicular mucinosis is
the deep, follicular, and perifollicular localization of the neoplastic
infiltrates, which makes them less accessible to skin-targeted therapies.
Clinical features. Folliculotropic MF occurs mostly in adults,
but may occasionally affect children and adolescents. Males are
more often affected than females. Patients may present with
grouped follicular papules, acneiform lesions, indurated plaques,
and sometimes tumors, which preferentially involve and are most
pronounced in the head and neck area.68 The skin lesions are often
associated with alopecia, and sometimes with mucinorrhea. Infil-
trated plaques in the eyebrows with concurrent alopecia are a
common and highly characteristic finding (Figure 2A). Unlike in
classical MF, pruritus is often severe, and may represent a good
parameter of disease progression. Secondary bacterial infections
are frequently observed.
Histopathology. Characteristic findings include the primarily
perivascular and periadnexal localization of the dermal infiltrates
Figure 1. Mycosis fungoides. (A) Typical patches and plaques on the trunk. (B)
Infiltration of atypical T cells into the epidermis with formation of Pautrier microab-
scess (hematoxylin and eosin [H&E] staining; original magnification,  200). The
image in panel B was obtained through a Leica DM6000B microscope (Leica,
Rijswijk, the Netherlands). Image acquisition was performed with a ProgResC10
camera and software (JenaOptik, Jena, Germany). An HC Plan APO 40/0.85
objective was used.
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with variable infiltration of the follicular epithelium by small,
medium-sized, or sometimes large hyperchromatic cells with
cerebriform nuclei, and sparing of the epidermis (folliculotropism
instead of epidermotropism; Figure 2B). Most cases show muci-
nous degeneration of the follicular epithelium (follicular mucino-
sis), as assessed with Alcian blue staining. There is often a
considerable admixture of eosinophils and sometimes plasma cells.
In most cases the neoplastic T cells have a CD3, CD4, CD8
phenotype as in classical MF. An admixture of CD30 blast cells
is common.
In some cases, prominent infiltration of both follicular epithe-
lium and eccrine sweat glands may be observed.68 Similar cases
with prominent infiltration of eccrine sweat glands, often associ-
ated with alopecia, have been designated as syringotropic MF.69,70
Prognosis. Recent studies described a disease-specific 5-year
survival of approximately 70%-80% in patients with folliculotropic
MF (Table 2), which is similar to that of classical tumor-stage MF,
but significantly worse than that of patients with classical plaque
stage MF.68,71
Treatment. Because of the perifollicular localization of the
dermal infiltrates, folliculotropic MF is often less responsive to
skin-targeted therapies, such as PUVA and topical nitrogen mus-
tard, than classical plaque-stage MF. In such cases total skin
electron beam irradiation is an effective treatment, but sustained
complete remissions are rarely achieved.68Alternatively, PUVA
combined with retinoids or interferon alpha may be considered,
whereas persistent tumors can be effectively treated with local
radiotherapy.
Pagetoid reticulosis. Definition. Pagetoid reticulosis is a vari-
ant of MF characterized by the presence of localized patches or
plaques with an intraepidermal proliferation of neoplastic T cells.
The term pagetoid reticulosis should only be used for the localized
type (Woringer-Kolopp type) and not for the disseminated type
(Ketron-Goodman type). Generalized cases would currently likely
be classified as aggressive epidermotropic CD8 CTCL, cutaneous
gamma/delta-positive T-cell lymphoma, or tumor-stage MF. 2,25,72
Clinical features. Patients present with a solitary psoriasiform
or hyperkeratotic patch or plaque, which is usually localized on the
extremities, and is slowly progressive. In contrast to classical MF,
extracutaneous dissemination or disease-related deaths have never
been reported.
Histopathology. The typical histologic picture shows a hyper-
plastic epidermis with marked infiltration by atypical pagetoid
cells, singly or arranged in nests. The atypical cells have medium-
sized or large, sometimes hyperchromatic and cerebriform nuclei,
and abundant, vacuolated cytoplasm. The upper dermis may show a
mixed infiltrate of lymphocytes or histiocytes, but does not contain
neoplastic T cells.
Immunophenotype. The neoplastic T cells may have either a
CD3, CD4, CD8 or a CD3, CD4, CD8 phenotype. CD30 is
often expressed.73,74
Treatment. The preferred mode of treatment is radiotherapy or
surgical excision. In some instances topical nitrogen mustard or
topical steroids may be an acceptable alternative.
Granulomatous slack skin. Definition. Granulomatous slack
skin (GSS) is an extremely rare subtype of CTCL characterized
by the slow development of folds of lax skin in the major skin
folds and histologically by a granulomatous infiltrate with
clonal T cells.75
Clinical features. This condition shows circumscribed areas of
pendulous lax skin with a predilection for the axillae and groins. In
approximately one-third of the reported patients, an association
with Hodgkin lymphoma was observed, and association with
classical MF has also been reported.75-77 Most patients have an
indolent clinical course (Table 2).
Histopathology. Fully developed lesions show dense granulo-
matous dermal infiltrates containing atypical T cells with slightly
indented to cerebriform nuclei, macrophages and often many
multinucleated giant cells, and destruction of elastic tissue. The
epidermis may show focal infiltration by small atypical T cells. The
atypical T cells have a CD3, CD4, CD8 phenotype.
Therapy. Radiotherapy may be effective, but experience is
limited. Rapid recurrences after surgical excision have been reported.
Se´zary syndrome
Definition. Se´zary syndrome (SS) is defined historically by the
triad of erythroderma, generalized lymphadenopathy, and the
presence of neoplastic T cells (Se´zary cells) in skin, lymph nodes,
and peripheral blood.78 In a recent report of the International
Society for Cutaneous Lymphomas (ISCL), criteria recommended
for the diagnosis of SS include one or more of the following: an
absolute Se´zary cell count of least 1000 cells/mm3; demonstration
of immunophenotypical abnormalities (an expanded CD4 T-cell
population resulting in a CD4/CD8 ratio more than 10, loss of any
or all of the T-cell antigens CD2, CD3, CD4, and CD5, or both); or
the demonstration of a T-cell clone in the peripheral blood by
molecular or cytogenetic methods.79 It is acknowledged that SS is
part of a broader spectrum of erythrodermic CTCL, and that
alternative staging systems for assessment of the degree of
peripheral blood involvement in these erythrodermic CTCLs have
been proposed.79,80 However, until the results of an ISCL study
investigating the clinical validity of these proposals are available,
demonstration of a T-cell clone (preferably of the same T-cell clone
in skin and peripheral blood) in combination with one of the
above-mentioned cytomorphologic or immunophenotypic criteria
are suggested as minimal criteria for the diagnosis of SS to exclude
patients with benign inflammatory conditions simulating SS.
Clinical features. SS is a rare disease and occurs exclusively in
adults. It is characterized by erythroderma, which may be associ-
ated with marked exfoliation, edema, and lichenification, and
which is intensely pruritic. Lymphadenopathy, alopecia, onychodys-
trophy, and palmoplantar hyperkeratosis are common findings.78
Histopathology. The histological features in SS may be similar
to those in MF. However, the cellular infiltrates in SS are more
often monotonous, and epidermotropism may sometimes be absent.
In up to one-third of biopsies from patients with otherwise classical
SS the histologic picture may be nonspecific.81,82 Involved lymph
Figure 2. Follicular mycosis fungoides. (A) Infiltrated plaques on the forehead and
right eyebrow showing hair loss. (B) Diffuse dermal infiltrate surrounding follicular
structures. Note infiltrate-free zone beneath epidermis (no epidermotropism) (H&E
staining; original magnification,  25). Image acquisition was performed as de-
scribed for Figure 1B. An HC FLUOTAR 2.5/0.07 objective was used.
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nodes characteristically show a dense, monotonous infiltrate of
Se´zary cells with effacement of the normal lymph node architec-
ture.83 Bone marrow may be involved, but the infiltrates are often
sparse and mainly interstitial.84
Immunophenotype. The neoplastic T cells have a CD3,
CD4, CD8 phenotype. In cases with a predominant CD3,
CD4, CD8 T-cell population in the skin and peripheral blood, the
diagnosis of actinic reticuloid should be considered.85 Circulating
Se´zary cells often show loss of CD7 and CD26.79
Genetic features. T-cell receptor genes are clonally rearranged.
Demonstration of clonal T cells in the peripheral blood is consid-
ered as an important diagnostic criterion allowing differentiation
between SS and benign forms of erythroderma.2,79,80 Recurrent
chromosomal translocations have not been detected in SS, but
complex karyotypes are common.86,87 Several studies have identi-
fied a consistent pattern of identical chromosomal abnormalities in
SS, which was almost identical to that in MF, suggesting that both
conditions represent parts of the same spectrum of disease with a
similar pathogenesis.88,89 Chromosomal amplification of the JUNB
gene, a member of the activator protein-1 (AP-1) transcription
factor complex involved in cell proliferation and T helper 2 (Th2)
cytokine expression by T cells, has been identified in SS.90,91
Prognosis and predictive factors. The prognosis is generally
poor, with a median survival between 2 and 4 years, depending on
the exact definition used.2,80 The disease-specific 5-year survival of
52 SS patients included in the Dutch and Austrian registries was
24% (Table 2). Most patients die of opportunistic infections that are
due to immunosuppression.
Therapy. Extracorporeal photopheresis (ECP), either alone or
in combination with other treatment modalities (eg, interferon
alpha), has been reported as an effective treatment in SS and
erythrodermic MF, with overall response rates of 30%-80%, and
complete response rates of 14%-25%.92,93 This great variation in
response rates may reflect differences in patient selection and/or
concurrent therapies. The suggested superiority of ECP over the
traditional low-dose chemotherapy regimens has not yet been
substantiated by controlled randomized trials.93 Beneficial results
have also reported of interferon alpha, either alone or in combina-
tion with PUVA therapy, prolonged treatment with a combination
of low-dose chlorambucil (2-4 mg/d) and prednisone (10-20 mg/d)
or with methotrexate (5-25 mg/wk), but complete responses are
uncommon. Skin-directed therapies like PUVA or potent topical
steroids may be used as adjuvant therapy. Recent studies report
beneficial effects of bexarotene and alemtuzumab (anti-CD52) but
the long-term effects of these therapies remain to be
established.58,62,94
Adult T-cell leukemia/lymphoma
Definition. Adult T-cell leukemia/lymphoma (ATLL) is a T-cell
neoplasm etiologically associated with the human T-cell leukemia
virus 1 (HTLV-1). Skin lesions are generally a manifestation of
widely disseminated disease. However, a slowly progressive form
that may have only skin lesions has been described (smoldering
variant).95
Clinical features. ATLL is endemic in areas with a high
prevalence of HTLV-1 in the population, such as southwest Japan,
the Caribbean islands, South America, and parts of Central Africa.
ATLL develops in 1% to 5% of seropositive individuals after more
than 2 decades of viral persistence. Most patients present with
acute ATLL characterized by the presence of leukemia, lymphad-
enopathy, organomegaly, hypercalcemia, and in about 50% skin
lesions, most commonly nodules or tumors (33%), generalized
papules (22%), or plaques (19%).96 Chronic and smoldering
variants frequently present with skin lesions, which may closely
resemble MF, whereas circulating neoplastic T cells are few
or absent.
Histopathology. Skin lesions show a superficial or more dif-
fuse infiltration of medium-sized to large T cells with pleomorphic
or polylobated nuclei, which often display marked epidermotro-
pism. The histologic picture may be indistinguishable from MF.
Skin lesions in the smoldering type may show sparse dermal
infiltrates with only slightly atypical cells. The neoplastic T cells
express a CD3, CD4, CD8 phenotype. CD25 is highly
expressed.95,96
Genetic features. T-cell receptor genes are clonally rearranged.
Clonally integrated HTLV-1 genes are found in all cases, and are
useful in differentiating between chronic or smoldering variants of
ATLL and classical MF or SS.97
Prognosis and predictive factors. Clinical subtype is the main
prognostic factor. Survival in acute and lymphomatous variants
ranges from 2 weeks to more than 1 year. Chronic and smoldering
forms have a more protracted clinical course and a longer survival,
but transformation into an acute phase with an aggressive course
may occur.95,96
Treatment. In most cases systemic chemotherapy is re-
quired.98,99 In chronic and smoldering cases mainly affecting the
skin, skin-targeted therapies as in MF may be used.
Primary cutaneous CD30 lymphoproliferative disorders
Primary cutaneous CD30 lymphoproliferative disorders (LPDs)
are the second most common group of CTCLs, accounting for
approximately 30% of CTCLs (Table 2). This group includes
primary cutaneous anaplastic large cell lymphoma (C-ALCL),
lymphomatoid papulosis (LyP), and borderline cases. It is now
generally accepted that C-ALCL and LyP form a spectrum of
disease, and that histologic criteria alone are often insufficient to
differentiate between these 2 ends of this spectrum.100 The clinical
appearance and course are used as decisive criteria for the definite
diagnosis and choice of treatment. The term “borderline case”
refers to cases in which, despite careful clinicopathologic correla-
tion, a definite distinction between C-ALCL and LyP cannot be
made. Clinical examination during further follow-up will generally
disclose whether the patient has C-ALCL or LyP.101
Primary cutaneous anaplastic large-cell lymphoma. Defini-
tion. Primary cutaneous anaplastic large cell lymphoma. (C-
ALCL) is composed of large cells with an anaplastic, pleomor-
phic, or immunoblastic cytomorphology and expression of the
CD30 antigen by the majority (more than 75%) of tumor cells.100
There is no clinical evidence or history of LyP, MF, or another
type of CTCL.
Clinical features. C-ALCL affects mainly adults with a male to
female ratio of 2-3:1. Most patients present with solitary or
localized nodules or tumors, and sometimes papules, and often
show ulceration (Figure 3).101,102 Multifocal lesions are seen in
about 20% of the patients. The skin lesions may show partial or
complete spontaneous regression, as in LyP. These lymphomas
frequently relapse in the skin. Extracutaneous dissemination occurs
in approximately 10% of the patients, and mainly involves the
regional lymph nodes.
Histopathology. There is a diffuse, nonepidermotropic infiltrate
with cohesive sheets of large CD30 tumor cells. In most cases the
tumor cells have the characteristic morphology of anaplastic cells,
showing round, oval, or irregularly shaped nuclei, prominent
eosinophilic nucleoli, and abundant cytoplasm (Figure 3). Less
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commonly (20%-25%), they have a nonanaplastic (pleomorphic or
immunoblastic) appearance.101,103 Reactive lymphocytes are often
present at the periphery of the lesions. Ulcerating lesions may show
a LyP-like histology with an abundant inflammatory infiltrate of
reactive T cells, histiocytes, eosinophils and/or neutrophils, and
relatively few CD30 cells. In such cases epidermal hyperplasia
may be prominent.
Immunophenotype. The neoplastic cells generally show an
activated CD4 T-cell phenotype with variable loss of CD2, CD5,
and/or CD3, and frequent expression of cytotoxic proteins (gran-
zyme B, TIA-1, perforin).104,105 Some cases (less than 5%) have a
CD8 T-cell phenotype. CD30 must be expressed by the majority
(more than 75%) of the neoplastic T cells.106 Unlike systemic
CD30 lymphomas, most C-ALCLs express the cutaneous lympho-
cyte antigen (CLA), but do not express epithelial membrane
antigen (EMA) and anaplastic lymphoma kinase (ALK), indicative
of the 2;5 chromosomal translocation or its variants.2,107,108 Unlike
Hodgkin and Reed-Sternberg cells in Hodgkin disease, staining for
CD15 is generally negative. Coexpression of CD56 is observed in
rare cases, but does not appear to be associated with an unfavorable
prognosis.109
Genetic features. Most cases show clonal rearrangement of
T-cell receptor genes. The (2;5)(p23;q35) translocation and its
variants, which is a characteristic feature of systemic ALCL, is not
or rarely found in C-ALCL.108
Prognosis and predictive factors. The prognosis is usually
favorable with a 10-year disease-related survival exceeding
90%.101,102 Patients presenting with multifocal skin lesions and
patients with involvement of only regional lymph nodes have a
similar prognosis to patients with only skin lesions.101 No differ-
ence in clinical presentation, clinical behavior, or prognosis is
found between cases with an anaplastic morphology and cases with
a nonanaplastic (pleomorphic or immunoblastic) morphology.101,103
Treatment. Radiotherapy or surgical excision is the first choice
of treatment in patients presenting with a solitary or few localized
nodules or tumors. Patients presenting with multifocal skin lesions
can best be treated with radiotherapy in case of only a few lesions,
or with low-dose methotrexate, as in LyP.101,110 Patients presenting
with or developing extracutaneous disease or rare patients with
rapidly progressive skin disease should be treated with doxorubicin-
based multiagent chemotherapy.
Lymphomatoid papulosis. Definition. Lymphomatoid papulo-
sis (LyP) is defined as a chronic, recurrent, self-healing papulone-
crotic or papulonodular skin disease with histologic features
suggestive of a (CD30) malignant lymphoma.
Clinical features. LyP generally occurs in adults (median age,
45 years; male-to-female ratio, 1.5:1), but may occur in children as
well.101,102,111,112 LyP is characterized by the presence of papular,
papulonecrotic, and/or nodular skin lesions at different stages of
development, predominantly on the trunk and limbs. Individual
skin lesions disappear within 3 to 12 weeks, and may leave behind
superficial scars (Figure 3). The duration of the disease may
vary from several months to more than 40 years. In up to 20% of
patients LyP may be preceded by, associated with, or followed
by another type of malignant (cutaneous) lymphoma, generally
MF, a (C-)ALCL, or Hodgkin lymphoma.101
Histopathology. The histologic picture of LyP is extremely
variable, and in part correlates with the age of the biopsied skin
lesion. Three histologic subtypes of LyP (types A, B, and C) have
been described, which represent a spectrum with overlapping
features.100,101,112 In LyP type A lesions, scattered or small clusters
of large, sometimes multinucleated or Reed-Sternberg–like, CD30
cells are intermingled with numerous inflammatory cells, such as
histiocytes, small lymphocytes, neutrophils, and/or eosinophils.
LyP type C lesions demonstrate a monotonous population or large
clusters of large CD30 T cells with relatively few admixed
inflammatory cells. LyP type B is uncommon (less than 10%) and is
characterized by an epidermotropic infiltrate of small atypical cells
with cerebriform nuclei similar to that observed in MF.
Immunophenotype. The large atypical cells in the LyP type A
and type C lesions have the same phenotype as the tumor cells in
C-ALCL.113 The atypical cells with cerebriform nuclei in the LyP
type B lesions have a CD3, CD4, CD8 phenotype and do not
express CD30 antigen.
Genetic features. Clonally rearranged T-cell receptor genes
have been detected in approximately 60%-70% of LyP lesions.114
Identical rearrangements have been demonstrated in LyP lesions
and associated lymphomas.115 The (2;5)(p23;q35) translocation is
not detected in LyP.108
Prognosis and predictive factors. LyP has an excellent progno-
sis. In a recent study of 118 LyP patients only 5 (4%) patients
developed a systemic lymphoma, and only 2 (2%) patients died of
systemic disease over a median follow-up period of 77 months.101
Risk factors for the development of a systemic lymphoma
are unknown.
Treatment. Since a curative therapy is not available and none of
the available treatment modalities affects the natural course of the
disease, the short-term benefits of active treatment should be
balanced carefully against the potential side effects.101 Low-dose
oral methotrexate (5-20 mg/wk) is the most effective therapy to
suppress the development of new skin lesions.110 Beneficial effects
have been reported of PUVA and topical chemotherapy. However,
after discontinuation of treatment the disease generally relapses
within weeks or months. Therefore, in patients with relatively few
and nonscarring lesions, long-term follow-up without active treat-
ment should be considered.
Subcutaneous panniculitis-like T-cell lymphoma
Definition. Subcutaneous panniculitis-like T-cell lymphoma (SPTL)
is defined as a cytotoxic T-cell lymphoma characterized by the
Figure 3. Primary cutaneous CD30 lymphoproliferative disease (pcCD30
LPD). (A) Diffuse dermal infiltrate of large atypical cells admixed with small
lymphocytes. (H&E staining; original magnification,  300). (B) The large atypical
cells are strongly positive for CD30. (C-D) The histologic picture in panels A and B can
be found both in C-ALC and in LyP. The final diagnosis depends on the clinical
presentation. In combination with the solitary tumor of the patient shown in panel C
the definite diagnosis will be C-ALC; in combination with recurrent, self-healing
papulonecrotic skin lesions (D), the final diagnosis is LyP. Image acquisition for
panels A and B was performed as described for Figure 1B. An HC Plan APO 20/0.70
objective was used.
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presence of primarily subcutaneous infiltrates of small, medium-
sized, or large pleomorphic T cells and many macrophages,
predominantly affecting the legs, and often complicated by a
hemophagocytic syndrome.12 Recent studies suggest that at least 2
groups of SPTL with a different histology, phenotype, and progno-
sis can be distinguished. Cases with an / T-cell phenotype are
usually CD8, are restricted to the subcutaneous tissue (no dermal
and/or epidermal involvement), and often run an indolent clinical
course.14,16,17,32 In contrast, SPTL with a / T-cell phenotype,
approximately 25% of all cases, are typically CD4, CD8, and
often coexpress CD56, the neoplastic infiltrates are not confined to
the subcutaneous tissue, but may involve the epidermis and/or
dermis as well, and invariably have a very poor progno-
sis.13,14,16,17,116 In the WHO-EORTC classification the term “SPTL”
is only used for cases with an / T-cell phenotype, whereas cases
with a / T-cell phenotype are included in the category of
cutaneous / T-cell lymphomas.32
Clinical features. SPTL occurs in adults as well as in young
children, and both sexes are equally affected. Patients generally
present with solitary or multiple nodules and plaques, which
mainly involve the legs, or may be more generalized (Figure 4A).
Ulceration is uncommon. Systemic symptoms such as fever,
fatigue, and weight loss may be present. The disease may be
complicated by a hemophagocytic syndrome, which is generally
associated with a rapidly progressive course.117 However, a hemo-
phagocytic syndrome is probably less common than in cutaneous
/ T-cell lymphomas with panniculitis-like lesions. Dissemination
to extracutaneous sites is rare. SPTL may be preceded for years or
decades by an seemingly benign panniculitis.15,17,117
Histopathology. Histopathology reveals subcutaneous infil-
trates simulating a panniculitis showing small, medium-sized, or
sometimes large pleomorphic T cells with hyperchromatic nuclei
and often many macrophages. The overlying epidermis and dermis
are typically uninvolved.16,116 Rimming of individual fat cells by
neoplastic T cells is a helpful, though not completely specific,
diagnostic feature (Figure 4B,C).32 Necrosis, karyorrhexis, and
cytophagocytosis are common findings. In the early stages the
neoplastic infiltrates may lack significant atypia and a heavy
inflammatory infiltrate may predominate.15,17,117
Immunophenotype. These lymphomas show a /, CD3,
CD4, CD8 T-cell phenotype, with expression of cytotoxic
proteins (Figure 4D).14,16,17,32 CD30 and CD56 are rarely, if
ever, expressed.
Genetic features. The neoplastic T cells show clonal T-cell
receptor (TCR) gene rearrangements. Specific genetic abnormali-
ties have not been identified. Epstein-Barr virus (EBV) is absent.
Prognosis and predictive factors. In contrast to prior reports
indicating that patients with a SPTL have a rapidly fatal course,
recent studies suggest that many patients with a SPTL (with a
CD8, / T-cell phenotype) have a protracted clinical course
with recurrent subcutaneous lesions but without extracutaneous
dissemination or the development of a hemophagocytic syn-
drome.17,32 Based on the few published reports in which appropri-
ate phenotyping was performed, the 5-year survival of such
patients may be more than 80%,32 which is consistent with the data
presented in Table 2.
Treatment. Patients have generally been treated with doxorubi-
cin-based chemotherapy and radiotherapy.12-17 However, recent
studies suggest that many patients can be controlled for long
periods of time with systemic corticosteroids.17,32
Extranodal NK/T-cell lymphoma, nasal type
Definition. Extranodal NK/T-cell lymphoma, nasal type, is a
nearly always EBV lymphoma of small, medium, or large cells
usually with an NK-cell, or more rarely a cytotoxic T-cell,
phenotype. The skin is the second most common site of involve-
ment after the nasal cavity/nasopharynx, and skin involvement may
be a primary or secondary manifestation of the disease. Since both
groups show an aggressive clinical behavior and require the same
type of treatment, distinction between “primary” and “secondary”
cutaneous involvement seems not useful for this category.16,19,32,118,119
Therefore, the WHO classification–derived term “extranodal NK/T-
cell lymphoma, nasal type,” rather than “(primary) cutaneous
NK/T-cell lymphoma, nasal type,” is preferred.
Clinical features. Patients are adults with a predominance of
males. This lymphoma is more common in Asia, Central America,
and South America. Patients generally present with multiple
plaques or tumors preferentially on the trunk and extremities, or in
the case of nasal NK/T-cell lymphoma with a midfacial destructive
tumor, previously also designated “lethal midline granu-
loma.”18,19,32,119-122 Ulceration is common. Systemic symptoms
such as fever, malaise, and weight loss may be present, and some
cases are accompanied by a hemophagocytic syndrome. The
disease is closely related to aggressive NK-cell leukemia, which
also may have cutaneous manifestations, and is also EBV associated.
Histopathology. These lymphomas show dense infiltrates in-
volving the dermis and often the subcutis. Epidermotropism may
be present. Prominent angiocentricity and angiodestruction are
often accompanied by extensive necrosis.18,19 NK/T-cell lymphoma
has a broad cytologic spectrum ranging from small to large cells,
with most cases consisting of medium-sized cells. The cells may
have irregular or oval nuclei, moderately dense chromatin, and
pale cytoplasm. In some cases a heavy inflammatory infiltrate of
small lymphocytes, histiocytes, plasma cells, and eosinophils
can be seen.
Immunophenotype. The neoplastic cells express CD2, CD56,
cytoplasmic CD3	, and cytotoxic proteins (TIA-1, granzyme B,
perforin), but lack surface CD3.122 In rare CD56 cases detection
of EBV by in situ hybridization and expression of cytotoxic
proteins are required for diagnosis (Figure 5B).3 Latent membrane
protein-1 (LMP-1) is inconsistently expressed.
Genetic features. The T-cell receptor is usually in germline
configuration, but can be rearranged in rare tumors with a cytotoxic
Figure 4. Subcutaneous panniculitis-like T-cell lymphoma. (A) Deeply seated
nodular skin lesions and residual lipodystrophy after disappearance of the skin
lesions. (B) Infiltrates are almost exclusively localized in subcutaneous tissue
resembling a lobular panniculitis (H&E staining; original magnification,  25). (C)
Rimming of individual fat cells by neoplastic T cells (H&E staining; original magnifica-
tion,  480). (D) Tumor cells show positive staining for CD8. Image acquisition for
panels B-D was performed as described for Figure 1B. An HC FLUOTAR 2.5/0.07
objective was used for panel B; an HC Plan APO 40/0.85 objective was used for
panels C and D.
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T-cell phenotype. EBV is expressed almost in all cases, suggesting
a pathogenetic role of this virus.18
Prognosis and predictive factors. Nasal-type NK/T-cell lym-
phoma presenting in the skin is a highly aggressive tumor with a
median survival of less than 12 months.18,19,120,121 The most
important factor predicting poor outcome is the presence of
extracutaneous involvement at presentation. In patients presenting
with only skin lesions, a median survival of 27 months was
reported, compared with 5 months for patients presenting with
cutaneous and extracutaneous disease.121 CD30, CD56 cases
reported to have a better prognosis may have been examples of
C-ALCL with coexpression of CD56.20
Therapy. Systemic chemotherapy is the first choice of treat-
ment, but the results are disappointing.120,121
Variant. Hydroa vacciniforme-like CTCL is a rare type of
EBV-associated lymphoma of CD8 cytotoxic T cells, which affects
children almost exclusively in Latin America and Asia.123-125 Patients
present with a papulovesicular eruption clinically resembling hydroa
vacciniforme, particularly on the face and upper extremities (sun-
exposed areas). The prognosis is poor.
Primary cutaneous peripheral T-cell lymphoma, unspecified
PTL, unspecified, in the WHO classification represent a heteroge-
neous group which includes all T-cell neoplasms that do not fit into
any of the better defined subtypes of T-cell lymphoma/leukemia.
Recent studies have suggested that primary cutaneous aggressive
epidermotropic CD8 cytotoxic T-cell lymphoma, cutaneous
gamma-delta T-cell lymphoma, and primary cutaneous small-
medium CD4 T-cell lymphoma can be separated out as provi-
sional entities. For the remaining diseases that do not fit into either
of these provisional entities the designation PTL, unspecified, is
maintained. In all cases a diagnosis of MF must be ruled out by
complete clinical examination and an accurate clinical history.
Primary cutaneous aggressive epidermotropic CD8 cytotoxic
T-cell lymphoma (provisional entity). Definition. Primary cuta-
neous aggressive epidermotropic CD8 CTCL is characterized by a
proliferation of epidermotropic CD8 cytotoxic T-cells and an
aggressive clinical behavior.25,26 Differentiation from other types of
CTCL expressing a CD8 cytotoxic T-cell phenotype, as observed
in more than 50% of patients with pagetoid reticulosis, and in rare
cases of MF, LyP, and C-ALCL, is based on the clinical presenta-
tion and clinical behavior.25 In these latter conditions, no difference
in clinical presentation or prognosis between CD4 and CD8
cases is found.
Clinical features. Clinically, these lymphomas are character-
ized by the presence of localized or disseminated eruptive papules,
nodules, and tumors showing central ulceration and necrosis or by
superficial, hyperkeratotic patches and plaques (Figure 5A).16,25
The clinical features are very similar to those observed in patients
with a cutaneous / T-cell lymphoma and cases described as
generalized pagetoid reticulosis (Ketron-Goodman type) in the
past.32 These lymphomas may disseminate to other visceral sites
(lung, testis, central nervous system, oral mucosa), but lymph
nodes are often spared.25
Histopathology. Histologically, these lymphomas show an ac-
anthotic or atrophic epidermis, necrotic keratinocytes, ulceration,
and variable spongiosis, sometimes with blister formation.16,25
Epidermotropism is often pronounced ranging from a linear
distribution to a pagetoid pattern throughout the epidermis (Figure
5B). Invasion and destruction of adnexal skin structures are
commonly seen. Angiocentricity and angioinvasion may be present.
Tumor cells are small-medium or medium-large with pleomorphic
or blastic nuclei.
Immunophenotype. The tumor cells have a betaF1, CD3,
CD8, granzyme B, perforin, TIA-1, CD45RA, CD45RO,
CD2, CD4, CD5, CD7/ phenotype (Figure 5C and
5D).11,16,25,26,32 EBV is generally negative.
Genetic features. The neoplastic T cells show clonal TCR
gene rearrangements. Specific genetic abnormalities have not
been described.
Prognosis and predictive factors. These lymphomas often have
an aggressive clinical course with a median survival of 32
months.25 There is no difference in survival between cases with a
small- or large-cell morphology.11
Therapy. Patients are generally treated with doxorubicin-based
multiagent chemotherapy.
Cutaneous gamma/delta T-cell lymphoma (provisional entity).
Definition. Cutaneous gamma/delta T-cell lymphoma (CGD-TCL)
is a lymphoma composed of a clonal proliferation of mature,
activated gamma/delta T cells with a cytotoxic phenotype. This
group includes cases previously known as SPTL with a gamma/
delta phenotype. A similar and possibly related condition may
present primarily in mucosal sites.28 Whether cutaneous and
mucosal gamma/delta TCL are all part of a single disease (ie,
muco-cutaneous gamma/delta TCL) is not yet clear.29,122 Distinc-
tion between “primary” and “secondary” cutaneous cases is not
useful in this group, since both groups have a very grim prognosis.
Clinical features. Patients with CGD-TCL generally present
with disseminated plaques and/or ulceronecrotic nodules or tu-
mors, particularly on the extremities, but other sites may be
affected as well.27-31 Involvement of mucosal and other extranodal
sites is frequently observed,28 but involvement of lymph nodes,
spleen, or bone marrow is uncommon. A hemophagocytic syn-
drome may occur in patients with panniculitis-like tumors.12,31
Histopathology. Three major histologic patterns of involve-
ment can be present in the skin: epidermotropic, dermal, and
subcutaneous. Often more than one histologic pattern is present in
the same patient in different biopsy specimens or within a single
biopsy specimen.27,31 The neoplastic cells are generally medium to
large in size with coarsely clumped chromatin. Large blastic cells
with vesicular nuclei and prominent nucleoli are infrequent.
Apoptosis and necrosis are common, often with angioinvasion. The
Figure 5. Primary cutaneous aggressive epidermotropic CD8 cytotoxic T-cell
lymphoma. (A) Typical presentation with nodules and tumors showing central
ulceration. (B-D) Tumor cells show striking epidermotropism (H&E staining; original
magnification,  150), and strongly express CD8 (C) and TIA-1 (D). Image acquisi-
tion for panels B-D was performed as described for Figure 1B. An HC Plan APO
10/0.40 objective lens was used.
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subcutaneous cases may show rimming of fat cells, similar to SPTL
of alpha/beta origin.
Immunophenotype. The tumor cells characteristically have a
betaF1, CD3, CD2, CD5, CD7/, CD56 phenotype with
strong expression of cytotoxic proteins. Most cases lack both CD4
and CD8, though CD8 may be expressed in some cases.29,31 In
frozen sections the cells are strongly positive for TCR-delta. If only
paraffin sections are available, the absence of betaF1 may be used
to infer a gamma/delta origin under appropriate circumstances.14,30
Genetic features. The cells show clonal rearrangement of the
TCR gamma gene. TCR beta may be rearranged or deleted, but is
not expressed. EBV is generally negative.28,31
Prognosis and predictive factors. Most patients have aggres-
sive disease resistant to multiagent chemotherapy and/or radia-
tion.27-32 In a recent series of 33 patients, a median survival of 15
months was noted.31 This study showed a trend for decreased
survival for patients who had subcutaneous fat involvement
compared with patients who had epidermal or dermal disease only.
Therapy. Patients should be treated with systemic chemo-
therapy, but the results are often disappointing.
Primary cutaneous CD4 small/medium-sized pleomorphic
T-cell lymphoma (provisional entity). Definition. Primary cuta-
neous CD4 small/medium-sized pleomorphic T-cell lymphoma is
a CTCL defined by a predominance of small- to medium-sized
CD4 pleomorphic T cells without (a history of) patches and
plaques typical of MF, and in most cases, a favorable clinical
course.2 In contrast to the EORTC classification, in the WHO-
EORTC classification the term “small/medium-sized pleomorphic
CTCL” is restricted to cases with a CD4 T-cell phenotype. Cases
with a CD3, CD4, CD8 phenotype usually have a more
aggressive clinical course are included in the group of aggressive
epidermotropic CD8 CTCLs.11
Clinical features. Characteristically, these lymphomas present
with a solitary plaque or tumor, generally on the face, the neck, or
the upper trunk (Figure 6A). Less commonly, they present with one
or several papules, nodules, or tumors.10,11,126-128
Histologic features. These lymphomas show dense, diffuse, or
nodular infiltrates within the dermis with a tendency to infiltrate the
subcutis. Epidermotropism may be present focally. There is a
predominance of small/medium-sized pleomorphic T cells (Figure
6B). A small proportion (less than 30%) of large pleomorphic cells
may be present.10 In some cases a considerable admixture with
small reactive lymphocytes and histiocytes may be observed.
Immunophenotype. By definition these lymphomas have a
CD3, CD4, CD8, CD30 phenotype, sometimes with loss of
pan–T-cell markers. Cytotoxic proteins are generally not expressed.11
Genetic features. The TCR genes are clonally rearranged.126,128
No consistent cytogenetic abnormalities have yet been identified.
Demonstration of an aberrant T-cell phenotype and clonality are
useful criteria to differentiate these small/medium-sized pleomor-
phic CTCLs from pseudo–T-cell lymphomas, which may also
present with a solitary plaque or nodule.129
Prognosis and predictive factors. These lymphomas have a
rather favorable prognosis, with an estimated 5-year survival of
approximately 60% to 80% (Table 2).2,4,5,10,11,126-128 Particularly,
cases presenting with a solitary or localized skin lesions seem to
have an excellent prognosis.11
Therapy. In patients with solitary localized skin lesions, surgi-
cal excision or radiotherapy is the preferred mode of treatment.
Cyclophosphamide as single-agent therapy and interferon alpha
have been reported effective in patients with more generalized skin
disease.128 However, the optimal treatment for this group has still to
be defined.
Primary cutaneous peripheral T-cell lymphoma, unspecified.
Definition. The designation PTL, unspecified, is maintained for
cutaneous T-cell lymphomas that do not fit into any of the better
defined subtypes of CTCL. Hence, other categories of T-cell
lymphoma must be excluded. These include the 3 provisional
entities described earlier.
Clinical features. Patients are commonly adults, who present
with solitary, localized, or more frequently generalized nodules or
tumors.2,4,10,11 No sites of predilection have been recorded.
Histopathology. Skin lesions show nodular or diffuse infiltrates
with variable numbers of medium- to large-sized pleomorphic or
immunoblast-like T cells. Epidermotropism is generally mild or
absent. Large neoplastic cells represent at least 30% of the total
tumor cell population.10
Immunophenotype. Most cases show an aberrant CD4 T-cell
phenotype with variable loss of pan–T-cell antigens. CD30 staining
is negative or restricted to a few scattered tumor cells. Rare cases
may show coexpression of CD56. Expression of cytotoxic proteins
is uncommon.11
Prognosis and predictive factors. The prognosis is generally
poor, with 5-year survival rates of less than 20% (Table 2).2,4,5,10,11
No statistical differences in survival were found between cases
presenting with solitary/localized lesions and cases presenting with
generalized skin lesions.11
Treatment. Patients should be treated with multiagent
chemotherapy.
Precursor hematologic neoplasm
CD4/CD56 hematodermic neoplasm (blastic
NK-cell lymphoma)
Definition. In the WHO classification, blastic NK-cell lymphoma
was included as a clinically aggressive neoplasm with a high
incidence of cutaneous involvement and risk of leukemic dissemi-
nation. The blastic cytologic appearance and CD56 expression
initially suggested an NK-precursor origin.3 More recent studies
suggest derivation from a plasmacytoid dendritic cell precursor.23,24
“CD4/CD56 hematodermic neoplasm”22 and “early plasmacy-
toid dendritic cell leukemia/lymphoma”23 have been suggested as
more appropriate terms for this condition.
Clinical features. CD4/CD56 hematodermic neoplasm com-
monly presents in the skin with solitary or multiple nodules or
tumors with or without concurrent extracutaneous localizations
(Figure 7A).21-24,32 About half of the patients have nodal or bone
marrow involvement at presentation.23,121 Most patients presenting
with only skin lesions rapidly develop involvement of bone
marrow, peripheral blood, lymph nodes, and extranodal sites.23,121
CD4/CD56 hematodermic neoplasm should be differentiated
Figure 6. Primary cutaneous CD4 small/medium-sized pleomorphic T-cell
lymphoma. (A) Presentation with a solitary tumor on the scalp. (B) Diffuse dermal
infiltrate mainly composed of small pleomorphic T cells with few scattered blasts cells
(H&E staining; original magnification,  750). Image acquisition was performed as
described for Figure 1B. An HC FLUOTAR 63/0.90 objective lens was used.
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above all from myelomonocytic leukemia cutis, and are conceptu-
ally similar to so-called “aleukemic leukemia cutis.”32
Histopathology. These lymphomas show nonepidermotropic,
monotonous infiltrates of medium-sized cells with finely dispersed
chromatin, and absent or indistinct nucleoli resembling lympho-
blasts or myeloblasts (Figure 7B).3,21-24 The cells have sparse
cytoplasm. Mitotic figures are frequent. Inflammatory cells are
absent. There is generally no necrosis or angioinvasion.
Immunophenotype. The tumor cells usually have a CD4,
CD56, CD8, CD7/, CD2/, CD45RA phenotype, but do not
express surface and cytoplasmic CD3 or cytotoxic proteins (Figure
7C).3,23 TdT and CD68 may be positive. Since lymphoblastic and
myeloblastic neoplasms can also be positive for CD56, stains for
CD3 and myeloperoxidase should always be performed in order to
exclude these entities.3 The cells express CD123 and TCL1, both of
which support a relationship to plasmacytoid dendritic cells.23,24,130
Genetic features. T-cell receptor genes are in germline configu-
ration. Tumor cells are negative for EBV.
Prognosis and predictive factors. CD4/CD56 hematoder-
mic neoplasm is an aggressive disease with a poor prognosis
(median survival, 14 months).21-24,121 Systemic chemotherapy usu-
ally results in a complete remission, but quick relapses unrespon-
sive to further chemotherapy are the rule. No significant difference
in survival is found between patients presenting with skin lesions
with or without concurrent extracutaneous disease.121
Recent studies suggest that patients can best be treated with
regimens used in acute leukemias.121
Cutaneous B-cell lymphomas
Primary cutaneous marginal-zone B-cell lymphoma
Definition. Primary cutaneous marginal zone B-cell lymphoma
(PCMZL) is an indolent lymphoma composed of small B cells,
including marginal zone (centrocyte-like) cells, lymphoplasmacy-
toid cells, and plasma cells. It includes cases previously designated
as primary cutaneous immunocytoma,131 and cases of cutaneous
follicular lymphoid hyperplasia with monotypic plasma cells.132
Exceptional cases of primary cutaneous plasmacytoma without
underlying multiple myeloma (extramedullary plasmacytoma of
the skin) show considerable overlap with PCMZL and are therefore
included in this category.133 PCMZL is considered part of the broad
group of extranodal marginal zone B-cell lymphomas commonly
involving mucosal sites, called MALT (mucosa-associated lym-
phoid tissue) lymphomas.
Clinical features. In most instances patients with PCMZL
present with red to violaceous papules, plaques, or nodules
localized preferentially on the trunk or extremities, especially the
arms. In contrast to PCFCL, presentation with multifocal skin
lesions is frequent (Figure 8). Ulceration is uncommon. PCMZLs
have a tendency to recur in the skin, but dissemination to
extracutaneous sites is exceedingly rare.131,134-136 In some cases
spontaneous resolution of the skin lesions may be observed. The
development of anetoderma in spontaneously resolving lesions has
been observed.137 An association with Borrelia burgdorferi infec-
tion has been reported in a significant minority of European cases
of PCMZL, but not in Asian cases or cases from the United
States.134,138-140 Associated autoimmune diseases are uncommon in
PCMZL, but rather suggest secondary cutaneous involvement of a
systemic lymphoma.131
Histopathology. These lymphomas show nodular to diffuse
infiltrates with sparing of the epidermis. The infiltrates are com-
posed of small lymphocytes, marginal zone B cells (centrocyte-like
cells), lymphoplasmacytoid cells, and plasma cells, admixed with
small numbers of centroblast- or immunoblast-like cells and many
reactive T cells. Reactive germinal centers are frequently observed.
They may be surrounded by a population of small- to medium-
sized cells with irregular nuclei, inconspicuous nucleoli, and
abundant pale cytoplasm (marginal zone B cells). Monotypic
plasma cells are often located at the periphery of the infiltrates and
in the superficial dermis beneath the epidermis.131,132,135,136 periodic
acid-schiff (PAS) intranuclear or intracytoplasmic inclusions may
be present in cases with a predominance of lymphoplasmacytoid
cells. PCMZLs rarely show transformation into a diffuse large
B-cell lymphoma, but a relative increase in large transformed
cells can be seen in some cases.
Immunophenotype. The marginal zone B cells express CD20,
CD79a, and bcl-2, but are negative for CD5, CD10, and bcl-6,
which may be useful in distinction from PCFCL.141,142 Reactive
germinal centers are typically bcl-6, CD10, and bcl-2. Plasma
cells express CD138 and CD79a, but generally not CD20, and
show monotypic cytoplasmic immunoglobulin light chain expres-
sion on paraffin sections.
Genetic features. Immunoglobulin heavy chain (IgH) genes
are clonally rearranged. Recent studies suggest the presence of the
t(14;18)(q32;q21) involving the IGH gene on chromosome 14 and
the MLT gene on chromosome 18, and t(3;14)(p14.1;q32) involv-
ing IGH and FOXP1 genes, in a proportion of PCMZLs.143,144
However, other translocations observed in gastric MALT lympho-
mas, such as t(11;18)(q21;q21) and t(1;14)(p22;q32), have not been
found in PCMZL.45,145
Prognosis and predictive factors. The prognosis of PCMZL is
excellent with a 5-year survival close to 100% (Table 2).131-136
Therapy. Patients with a solitary or a few lesions can be treated
with radiotherapy or surgical excision. In patients with associated B
burgdorferi infection, systemic antibiotics should be tried first.146
For patients presenting with multifocal skin lesions, chlorambucil
or intralesional or subcutaneous administration of interferon alpha
Figure 8. Primary cutaneous marginal zone lymphoma. Characteristic clinical
presentation with multiple nodules and small tumors on the back and arms.
Figure 7. CD4/CD56 hematodermic neoplasm (blastic NK-cell lymphoma). (A)
Presentation with large tumor on the back. (B) Monotonous infiltration of medium-
sized tumor cells (H&E staining; original magnification,  480). (C) The tumor cells
strongly express CD56. Image acquisition for panels B and C was performed as
described for Figure 1B. An HC Plan APO 40/0.85 objective lens was used.
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may produce complete responses in approximately 50% of pa-
tients.146 Very good results have also been obtained with the use of
systemic or intralesional anti-CD20 antibody (rituximab).147 In
patients showing frequent skin relapses, topical or intralesional
steroids may be considered; alternatively, an expectant strategy can
be followed, similar to that used in other indolent B-cell lympho-
mas and leukemias.
Primary cutaneous follicle-center lymphoma
Definition. Primary cutaneous follicle center lymphoma (PCFCL)
is defined as a tumor of neoplastic follicle center cells, usually a
mixture of centrocytes (small and large cleaved follicle center
cells) and variable numbers of centroblasts (large noncleaved
follicle center cells with prominent nucleoli), with a follicular, a
follicular and diffuse, or a diffuse growth pattern, which generally
present on the head or trunk. Lymphomas with a diffuse growth
pattern and a monotonous proliferation of centroblasts and immu-
noblasts are, irrespective of site, excluded and are classified as
PCLBCL (Table 3).
Clinical features. PCFCL has a characteristic clinical presenta-
tion with solitary or grouped plaques and tumors, preferentially
located on the scalp or forehead or on the trunk, and rarely on the
legs (Figure 9A-B).33-35 Particularly on the trunk, these tumors may
be surrounded by erythematous papules and slightly indurated
plaques, which may precede the development of tumorous lesions
for months or even many years. In the past, PCFCLs with such a
typical presentation on the back were referred to as “reticulohistio-
cytoma of the dorsum” or “Crosti lymphoma (Figure 9A).”34,148
Presentation with multifocal skin lesions is observed in a small
minority of patients, but is not associated with a more unfavorable
prognosis.42,149 If left untreated, the skin lesions gradually
increase in size over years, but dissemination to extracutaneous
sites is uncommon.
Histopathology. PCFCLs show nodular to diffuse infiltrates
with almost constant sparing of the epidermis. The histologic
picture is variable, which relates primarily to the age and the
growth rate of the biopsied skin lesion as well as the location.35,39 A
clear-cut follicular growth pattern is more commonly observed in
lesions arising on the scalp than those presenting on the trunk.150
Small and early lesions contain a mixture of centrocytes, relatively
few centroblasts, and many reactive T cells. Large centrocytes,
often multilobated, are a common feature of PCFCL (Figure 9C).
The large neoplastic B cells may have a fibroblast-like appearance.
In small and/or early lesions a clear-cut follicular growth pattern or,
more often, remnants of a follicular growth pattern may be
observed. If present, the abnormal follicles are composed of
malignant bcl-6 follicle center cells enmeshed in a network of
CD21 or CD35 follicular dendritic cells. The follicles are
ill-defined, lack tingible body macrophages, and generally have a
reduced or absent mantle zone.150,151 With progression to tumorous
lesions the neoplastic B cells increase both in number and size,
whereas the number of reactive T cells steadily decreases.35,39
Follicular structures, if present before, are no longer visible except
for occasional scattered CD21 or CD35 follicular dendritic cells.
Tumorous skin lesions generally show a monotonous population of
large follicle center cells, generally large centrocytes and multilo-
bated cells, and in rare cases spindle-shaped cells, with a variable
admixture of centroblasts and immunoblasts.34,35,39,42,152 Usually, a
prominent stromal component is present.
Immunophenotype. The neoplastic cells express the B-cell–
associated antigens CD20 and CD79a, and may show monotypic
staining for surface immunoglobulins (sIgs). However, absence of
detectable sIg is common in tumorous lesions showing a diffuse
population of large follicle center cells. PCFCLs consistently
express bcl-6.141,142,151 CD10 expression is particularly observed in
cases with a follicular growth pattern, but is uncommon in PCFCLs
with a diffuse growth pattern.142,153 Staining for CD5 and CD43 is
negative. Unlike nodal and secondary cutaneous follicular lympho-
mas, PCFCLs do not express bcl-2 protein or show faint bcl-2
staining in a minority of neoplastic B-cells.36,41,150 (Figure 9D,E).
Staining for MUM-1/IRF4 is negative.46
Genetic features. Clonally rearranged immunoglobulin genes
are present. Somatic hypermutation of variable heavy and light
chain genes has been demonstrated, which further supports the
follicle center cell origin of these lymphomas.154,155 In most studies
PCFCLs, including cases with a follicular growth pattern, do not
Figure 9. Primary cutaneous follicle center lymphoma. (A) Typical presentation
with tumors on the chest surrounded by less infiltrated erythematous skin lesions. (B)
Presentation with multiple tumors confined to the scalp. (C) Diffuse dermal infiltrate
mainly consisting of large centrocytes and multilobated cells (H&E staining; original
magnification, 480). (D-E) Serial sections stained for CD20 (D) and bcl-2 (E). Bcl-2
is expressed by perivascular T cells, but not by the neoplastic B cells. Image
acquisition for panels A and C-E was performed as described for Figure 1B. An HC
Plan APO objective was used (40/0.85 for panel C; 10/0.40 for panels D and E).
Table 3. Characteristic features of PCFCL and PCLBCL, leg type
PCFCL PCLBCL, leg type
Morphology Predominance of centrocytes
that are often large,
especially in diffuse
lesions.
Predominance or confluent sheets
of medium-sized to large B cells
with round nuclei, prominent
nucleoli, and coarse chromatin
resembling centroblasts and/or
immunoblasts.
Centroblasts may be present,
but not in confluent sheets.
Diffuse growth pattern.
Growth pattern may be
follicular, follicular and
diffuse, or diffuse (a
continuum without distinct
categories or grades).
Phenotype Bcl-2: /* Bcl-2: ‡
Bcl-6:  Bcl-6: /
CD10: /† CD10: 
Mum-1:  Mum-1: 
Clinical
features
Middle-aged adults. Elderly, especially females,
Localized lesions on head or
trunk (90%).
Lesions localized on leg(s), most
often below the knee.
Multifocal lesions in rare
cases.
Rare cases with lesions at other
sites than the leg (10%).
*Faint staining, when present; minority of cells (see comments in paragraph on
PCFCL)
†Diffuse lesions, mostly CD10.
‡Strong staining; in most neoplastic cells.
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show the t(14;18), which is characteristically found in systemic
follicular lymphomas and a proportion of systemic diffuse large
B-cell lymphoma.37,41,151,153 (see “Comment” under “Primary cuta-
neous follicle-center lymphoma”).
Inactivation of p15 and p16 tumor suppressor genes by promo-
tor hypermethylation has been reported in about 10% and 30% of
PCFCLs, respectively.156 Chromosomal imbalances have been
identified by comparative genomic hybridization (CGH) analysis in
a minority of PCFCLs, but a consistent pattern has not yet
emerged.44,157 In a recent study using interphase fluorescence in
situ hybridization, no evidence for translocations involving IgH,
myc, or bcl-6 loci were found.45 PCFCLs have the gene expression
profile of germinal center–like large B-cell lymphomas.46
Prognosis and predictive factors. Regardless of the growth
pattern (follicular or diffuse), the number of blast cells, or the
presence of either localized or multifocal skin disease, these
PCFCLs have an excellent prognosis with a 5-year survival of more
than 95% (Table 2).2,4,5,33-35,38,42,150,151 A recent study suggests that
strong expression of bcl-2 in PCFCLs with a diffuse large-cell
histology is associated with a more unfavorable prognosis.158
Therapy. In patients with localized or few scattered skin
lesions, radiotherapy is the preferred mode of treatment, even in
cases with a predominance of large “cleaved” cells.38,42,149,159-161
Cutaneous relapses, observed in approximately 20% of patients, do
not indicate progressive disease and can be treated with radio-
therapy as well. Anthracycline-based chemotherapy is required
only in patients with very extensive cutaneous disease and patients
developing extracutaneous disease.42,150 Recent studies report
beneficial effects of systemic or intralesional administration of
anti-CD20 antibody (rituximab) therapy in small series of PCFCLs,
but the long-term effects of this approach have yet to be
determined.162-164
Comment. Characteristically, PCFCLs do not express bcl-2
protein, or show faint bcl-2 staining in a minority of tumor cells,
and do not show the t(14;18).36,37,41 However, recent studies report
the presence of t(14;18) and/or bcl-2 expression in a significant
minority of PCFCLs.43,153,165-167 Whether these discrepant results
are the result of differences in patient selection (eg, incomplete
staging) or different definitions for bcl-2 positivity, or represent
regional differences is as yet unknown. Importantly, in PCFCLs
with a follicular growth pattern there are no differences in clinical
presentation and behavior between bcl-2 and/or t(14;18)-positive
and -negative cases.36,152,165-167 In contrast, recent studies suggest
that expression of bcl-2 protein by more than 50% of the neoplastic
B cells in PCFCLs with a diffuse proliferation of large centrocytes,
observed in approximately 15% of cases, is associated with a more
unfavorable prognosis.158 Further studies are warranted to define
the clinical and biological significance of bcl-2 expression and/or
the presence of t(14;18) observed in some cases of PCFCL.
Notwithstanding, demonstration of bcl-2 expression and/or t(14;
18) should always raise suspicion of a systemic lymphoma
involving the skin secondarily.
Primary cutaneous diffuse large B-cell lymphoma, leg type
Definition. Primary cutaneous diffuse large B-cell lymphoma, leg
type, is a PCLBCL with a predominance or confluent sheets of
centroblasts and immunoblasts, characteristically presenting with
skin lesions on the (lower) legs. Uncommonly, skin lesions with a
similar morphology and phenotype can arise at sites other than
the legs.
Clinical features. PCLBCL, leg type, predominantly affects
elderly patients, particularly females.40,42,43 Patients present with
generally rapidly growing red or bluish-red tumors on one or both
(lower) legs (Figure 10A). In contrast to the group of PCFCLs,
these lymphomas more often disseminate to extracutaneous sites
and have a more unfavorable prognosis.40,42 Reports on PCLBCL,
leg type, arising at sites other than the leg are few. In a recent
European multicenter study, 16 of 17 patients presented with
solitary or localized skin lesions either on the trunk or head, and 7
of 17 patients developed extracutaneous disease.42
Histopathology. These lymphomas show diffuse infiltrates,
which often extend into the subcutaneous tissue. These infiltrates
generally show a monotonous population or confluent sheets of
centroblasts and immunoblasts (Figure 10B).40,42 Mitotic figures
are frequently observed. Small B cells are lacking and reactive T
cells are relatively few and often confined to perivascular areas. A
prominent stromal reaction as in PCFCLs is not observed.
Immunophenotype. The neoplastic B cells express monotypic
sIg and/or cIg and B-cell–associated antigens CD20 and CD79a. In
contrast to the group of PCFCLs, PCLBCL, leg type, shows strong
bcl-2 expression, also in cases not located on the legs (Figure
10C).41,43,142,158 Bcl-6 is expressed by most cases, whereas CD10
staining is generally absent.142 Unlike PCFCL, most PCLBCL, leg
types, express MUM-1/IRF4 protein (Figure 10D).46,168
Genetic features. The t(14;18) is not found in PCLBCLs,
although strong bcl-2 expression is common in this group.41,43 In
some cases bcl-2 overexpression may result from chromosomal
amplification of the bcl-2 gene.157 Inactivation of p15 and p16
tumor suppressor genes by promotor hypermethylation has been
detected in 11% and 44% of PCLBCLs, respectively.156 Chromo-
somal imbalances have been identified in up to 85% of PCLBCLs,
with gains in 18q and 7p and loss of 6q as most common
findings.44,157 Recent studies demonstrated translocations involving
myc, bcl-6, and IgH genes in 11 of 14 PCLBCL-leg cases, but not in
patients with a PCFCL with a diffuse infiltration of large centro-
cytes.45 Recent studies suggest that patients with PCLBCL-leg
have an activated B-cell gene expression profile.46
Prognosis and predictive features. The 5-year survival of 78
cases included in the Dutch and Austrian registries was 55% (Table
2). PCLBCLs on the leg have an inferior prognosis compared to
PCLBCLs presenting at other sites.42 The presence of multiple skin
lesions at diagnosis is a significant adverse risk factor. In a recent
study, patients presenting with a single skin tumor on one leg had a
disease-related 5-year survival of 100%, whereas patients present-
ing with multiple skin lesions on one or both legs had a
disease-related 5-year survival of 45% and 36%, respectively.42
Figure 10. Primary cutaneous diffuse large B-cell lymphoma, leg type. (A)
Clinical presentation with multiple tumors on right lower leg. (B) Monotonous
proliferation of centroblasts and immunoblasts (H&E staining; original magnification,
 480). (C-D) Characteristically, the neoplastic B cells strongly express bcl-2 (C) and
Mum-1/IRF-4 (D). Image acquisition for panels B-D was performed as described for
Figure 1B. An HC Plan APO objective was used (40/0.85 for panel B; 20/0.70 for
panels C and D).
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Therapy. These lymphomas should be treated as systemic
diffuse large B-cell lymphomas with anthracycline-based chemo-
therapy.40,42 In patients presenting with a single small skin tumor,
radiotherapy may sometimes be considered.42 Systemic administra-
tion of anti-CD20 antibody (rituximab) has proved effective in
some patients, but long-term follow-up data are not available and
the place of rituximab in the treatment of PCLBCL, either as single
agent therapy or in combination with systemic chemotherapy
remains to be established.162,169
Primary cutaneous diffuse large B-cell lymphoma, other
The term “PCLBCL, other,” refers to rare cases of large B-cell
lymphomas arising in the skin, which do not belong to the group of
PCLBCL, leg type, or the group of PCFCLs. These cases include
morphologic variants of diffuse large B-cell lymphoma, such as
anaplastic or plasmablastic subtypes or T-cell/histiocyte rich large
B-cell lymphomas. Such cases are generally a skin manifestation of
a systemic lymphoma. Plasmablastic lymphomas are seen almost
exclusively in the setting of HIV infection or other immune
deficiencies.170-172 Some of these cases had only skin lesions at
presentation. Rare cases of primary cutaneous T-cell/histiocyte-rich
B-cell lymphoma, characterized by the presence of large scattered
B cells in a background of numerous reactive T cells, have been
reported.173,174 Clinically, they show similarities with the groups of
PCFCL and PCMZL. These lymphomas commonly present with
skin lesions on the head, the trunk or the extremities, and may in
fact represent an exaggerated T-cell infiltrate in association with
other forms of CBCL. Unlike their nodal counterparts, they appear
to have an excellent prognosis.173,174 In addition, rare cases of
primary cutaneous intravascular large B-cell lymphoma may be
included in this category.
Intravascular large B-cell lymphoma. Intravascular large B-
cell lymphoma is a well-defined subtype of large B-cell lymphoma,
defined by an accumulation of large neoplastic B cells within blood
vessels. These lymphomas preferentially affect the central nervous
system, lungs, and skin and are generally associated with a poor
prognosis.175
Patients often have widely disseminated disease, but cases with
only skin involvement may occur. Clinically, intravascular large
B-cell lymphoma may present with violaceous patches and plaques
or teleangiectatic skin lesions usually on the (lower) legs or the
trunk.175,176 Patients presenting with only skin lesions appear to
have a significantly better survival than patients with other clinical
presentations (3-year overall survival: 56% versus 22%).176 Interest-
ingly, colonization of cutaneous cherry hemangiomas by neoplastic
cells as the only presenting sign of intravascular large B-cell
lymphoma has been reported.177-178 Histologically, dilated blood
vessels in the dermis and subcutis are filled and often extended by a
proliferation of large neoplastic B cells. These cells may cause
vascular occlusion of venules, capillaries, and arterioles. In some
cases small numbers of tumor cells can also be observed around
blood vessels. Multiagent chemotherapy is the preferred mode of
treatment, also in patients presenting with skin-limited disease.176
Conclusions and future directions
The WHO-EORTC classification for cutaneous lymphomas pre-
sented herein may be considered as an important step forward.
First, the development of this consensus classification will put an
end to the ongoing discussion whether the EORTC or the WHO
scheme can best be used, and is expected to contribute to a more
uniform diagnosis and hence a more uniform treatment of patients
with a cutaneous lymphoma. Second, major progress has been
made in a better definition of some controversial groups of
cutaneous lymphoma, in particular the group of PCFCL/PCLBCL
and the group of CTCL other than MF, SS, and the group of
primary cutaneous CD30 LPD.
The new definitions of the groups of PCFCL, PCLBCL, leg
type, and PCLBCL, other, will allow a more reliable distinction
between indolent and more aggressive types of CBCL, and
facilitate the decision whether radiotherapy or systemic chemo-
therapy should be selected as first choice of treatment. Large
multicenter studies are now required to validate the current
proposals, and in particular to investigate the diagnostic and
prognostic value of bcl-2 and Mum-1/IRF4 protein expression.
The classification of CTCL other than MF, SS, and the group of
primary cutaneous CD30 LPD is still difficult, as it requires
accurate clinicopathologic correlation and a number of complemen-
tary techniques to arrive at a definite diagnosis. SPTL (with an
alpha/beta phenotype), extranodal NK/T-cell lymphoma, nasal
type, and CD4/CD56 hematodermic neoplasm are now fairly
well-defined. However, considerable overlap is noted between
cutaneous (and mucosal) GD-TCL and aggressive epidermotropic
CD8 CTCL. The similarities in clinical presentation and pattern
of dissemination between these conditions may reflect similarities
in homing profile and biologic function of normal gamma/delta-
positive T-cells and activated CD8 cytotoxic T cells, respectively.
Apart from the group of SPTLs and the group of CD4 small/
medium-sized pleomorphic CTCLs, these rare types of CTCL have
a very poor prognosis and are generally resistant to conventional
chemotherapy. More aggressive regimens, including allogeneic
bone marrow transplantation, for patients with aggressive types of
CTCL including advanced stages of MF and SS are currently under
investigation.179,180
Recently, studies have started to investigate gene and protein
expression profiles in different types of cutaneous lymphoma. It is
expected that these studies will not only contribute to a better
understanding of the molecular pathways involved in the develop-
ment and progression of these lymphomas, but will also provide
new molecular targets for diagnosis and therapeutic intervention,
and ultimately to more refined classification schemes.
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Erratum
In the article by Nick et al entitled “Recombinant human activated protein C
reduces human endotoxin-induced pulmonary inflammation via inhibition of
neutrophil chemotaxis,” which appeared in the December 15, 2004, issue of
Blood (Volume 104:3878-3885), the lipopolysaccharide (LPS) administered
to volunteers was incorrectly described: the wrong E coli strain was
described. The LPS used in the study was actually derived from E coli strain
O:113 (provided by the National Institutes of Health, Bethesda, MD).
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